Single Agent Chemotherapy Market size is estimated to reach $8.2 billion by 2030; increasing incidence of cancer, government investments in healthcare infrastructure, advances in drug development, the approval of new single agent chemotherapeutic drugs and the increasing investment in healthcare are driving the demand for Single Agent Chemotherapy.

Single Agent Chemotherapy Market size is estimated to reach $8.2 billion by 2030, growing at a CAGR of 3.9% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Single Agent Chemotherapy Market – By Drug Class (Alkylating Agents, Antimetabolites, Anti-tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Others), By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia, Lymphoma, Other Cancers), By Route of Administration (Intravenous (IV), Oral, Subcutaneous (SC), Intramuscular (IM)), By End User (Hospitals & Clinics, Specialty Centers and Others) and By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2024-2030.”

Single agent chemotherapy offers a targeted approach for various cancers such as breast, lung and colorectal cancers. The aging global population, which is more susceptible to cancer, further propels the market demand. In addition, the advancements in drug development couple with the approval of new single agent chemotherapy drugs also drives the market.

Geographically, North America held the largest share with 35% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030 owing to the advanced healthcare infrastructure, early adoption of treatments, substantial research investments and favourable regulatory environment propels the demand for Single Agent Chemotherapy Drugs. According to the 2024 report by the National Cancer Institute, breast, lung and bronchus, prostate, and colorectal cancers account for almost 50% of all new cancer cases in the United States. Lung and bronchus, colorectal, pancreatic, and breast cancers are responsible for nearly 50% of all deaths. As a result, there is a high demand for cancer treatment which drives the demand for single agent chemotherapy. 

Population growth and aging are key drivers of the world’s cancer burden. As per the UN, the global population reached about 8 billion people in 2022 and is projected to reach 9.7 billion by 2050. The aging population drives up the risk of cancer. A report from the American Cancer Society projects that by 2050 the number of people with cancer could rise 77%. As per the estimates, about 1 in 5 people who are alive currently will develop cancer in their lifetime and around 1 in 9 men and 1 in 12 women will die from the disease. As the burden of cancer increases, the demand for treatments will also rise, thereby driving the demand for single agent chemotherapy.

Rising government investments in healthcare and awareness programs are significantly driving the adoption of single agent chemotherapy. In November 2023, the UK Government and Prostate Cancer UK unveiled a screening trial to identify ways of detecting prostate cancer in the earlier stages. This trial, called TRANSFORM, will use innovative solutions such as magnetic resonance imaging (MRI) screening to identify cases not detected by blood tests and in the absence of cancer symptoms. Such programs enhance healthcare infrastructure by identifying the disease earlier leading to better outcomes once chemotherapy commences. Additionally, funding supports research and development resulting in more effective and safer chemotherapy options

Key companies profiled in the Single Agent Chemotherapy Market are F. Hoffmann-La Roche AG, Bristol Myers Squibb, AbbVie, Pfizer Inc., Janssen Biotech, GlaxoSmithKline, Novartis AG, AstraZeneca plc, Teva Pharmaceuticals Industries, Sanofi S.A and others

Oncology Market - Oncology Market size was valued at $136.7 billion in 2019 and is poised to grow at a CAGR of 11.9% during the forecast period 2020-2025 primarily attributed to the rising cancer cases. 

Chemotherapy-Induced Myelosuppression Treatment Market- Chemotherapy-Induced Myelosuppression Treatment Market size was valued at $14.3 billion in 2020 and is expected to grow with a CAGR of 3.4% during the forecast period 2021-2026.  Increasing prevalence of cancer across the globe coupled with rising aging population are driving the growth of the market.

Metastatic Melanoma Market - Metastatic Melanoma Market size is estimated to reach $12.1 billion by 2027, growing at a CAGR of 7.3% during the forecast period 2022-2027. The surging technological progress, increasing focus on immune checkpoint inhibitors and enhanced sophistication in healthcare facilities globally are set to drive the Metastatic Melanoma Market.